Explorez tous les épisodes du podcast Decera Clinical Education Oncology Podcast

Plongez dans la liste complète des épisodes de Decera Clinical Education Oncology Podcast. Chaque épisode est catalogué accompagné de descriptions détaillées, ce qui facilite la recherche et l'exploration de sujets spécifiques. Suivez tous les épisodes de votre podcast préféré et ne manquez aucun contenu pertinent.

	Titre	Date	Durée
	ROS1-Alterations and Molecular Testing in Advanced NSCLC	28 Aug 2024	00:16:28
In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the current understanding of ROS1 rearrangements in non-small-cell lung cancer tumor biology and its implications for molecular testing and treatment selection including: ROS1-gene fusions in advanced lung cancer ROS1 testing recommendations with DNA NGS, RNA NGS, FISH break apart assay, and IHC Comparative specificity of ROS1 and ALK targeting tyrosine kinase inhibitors Advantages of RNA- vs DNA-based next-generation sequencing Program faculty: Jessica J. Lin, MD Attending Physician Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Alice T. Shaw, MD, PhD Chief, Strategic Partnerships Attending Physician, Thoracic Oncology Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts Resources: To download the slides associated with this podcast discussion, please visit the program page Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers	05 Aug 2024	00:49:32
In this episode, listen to Floor J. Backes, MD, and Angeles Alvarez Secord, MD, MHSc, share their clinical insights and takeaways on new data presented for endometrial, ovarian, and cervical cancers presented at the 2024 annual meetings of the Society of Gynecologic Oncology and American Society of Clinical Oncology including: RUBY Part 1 Subgroup Analyses by MRR Status: Addition of dostarlimab to platinum-based therapy followed by dostarlimab maintenance in advanced endometrial cancer RUBY Part 2: Survival outcomes with addition of dostarlimab to platinum-based therapy followed by dostarlimab plus niraparib maintenance in advanced endometrial cancer Survival Analyses From Phase III NRG GY018: Carboplatin plus paclitaxel with or without pembrolizumab as frontline treatment for patients with advanced endometrial cancer DUO-E: First-line therapy with carboplatin plus paclitaxel plus bevacizumab and durvalumab followed by maintenance with bevacizumab, durvalumab, and olaparib in newly diagnosed endometrial cancer Long-term Follow-up From SIENDO: PFS in TP53 wild-type and preliminary survival by molecular subgroups in patients with endometrial cancer and complete or partial response after ≥12 weeks of first line taxane/carboplatin Subgroup Analyses From the Randomized Phase III MIRASOL: Mirvetuximab soravtansine vs investigator’s choice of chemotherapy in FR𝝰-high platinum-resistant ovarian cancer Subgroup Analyses of Raludotatug Deruxtecan (R-DXd): An anti-CDH6 antibody–drug conjugate in previously treated ovarian cancer Phase III CARACO Trial: Omission of lymphadenectomy in advanced ovarian cancer treated with interval cytoreductive surgery after neoadjuvant chemotherapy innovaTV 301/ENGOT-cx12/GOG-3057: Tisotumab vedotin vs investigator’s choice of chemotherapy in patients with advanced cervical cancer Randomized, Double-blind, Placebo-controlled Phase III Trial: Addition of pembrolizumab to concurrent chemoradiation in high-risk locally advanced cervical cancer Program faculty: Floor J. Backes, MD Professor Director of Clinical Research Division of Gynecologic Oncology Associate Fellowship Director Department of Obstetrics and Gynecology The Ohio State University College of Medicine The James Cancer Hospital and Solove Research Institute Columbus, Ohio Angeles Alvarez Secord, MD, MHSc Professor of Obstetrics & Gynecology Division of Gynecologic Oncology Director, Gynecologic Oncology Clinical Trials Associate Director, Clinical Research, Gynecologic Oncology Program Duke Cancer Institute Duke University Medical Center Durham, North Carolina Resources: To download the slides associated with this podcast discussion, please visit the program page. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	07 May 2024	00:47:23
In this episode, Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the NCCN CLL guidelines and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes. The greater discussion addresses: Optimal selection of therapy for treatment-naive CLL, including second-generation covalent BTK inhibitors Considerations in therapy selection for previously treated CLL Novel strategies for treating CLL Presenters: Danielle M. Brander, MD Assistant Professor of Medicine Division of Hematologic Malignancies and Cellular Therapy Duke Cancer Institute Durham, North Carolina Brian Hill, MD, PhD Director, Lymphoid Malignancies Program Staff Physician, Department of Hematology and Medical Oncology Taussig Cancer Institute Cleveland Clinic Cleveland, Ohio Deborah Stephens, DO Associate Professor Director of the CLL Program Lineberger Comprehensive Cancer Center University of North Carolina Chapel Hill, North Carolina Content based on a live and online CME program supported by educational grants from AstraZeneca; BeiGene, Ltd.; and Lilly. Link to full program including downloadable slides: https://bit.ly/49YxtSq Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Managing Serious Adverse Events Associated with BTK Inhibitor Treatment	27 Jul 2021	00:13:13
In this podcast episode, Amy Goodrich, CRNP, discusses nursing perspectives on managing serious adverse events associated with BTK inhibitor therapy. Topics in this podcast include: Atrial fibrillation Cardiac toxicity Musculoskeletal AEs Managing risk of infections Presenter: Amy Goodrich, RN, MSN, CRNP-AC Research Associate/Nurse Practitioner Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University Baltimore, Maryland CE/AAPA credit available by visiting the online program: https://bit.ly/3zMXFOp Link to full program, including downloadable slidesets: https://bit.ly/3iwN9Ub Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Strategies for Avoiding Adverse Reactions to BTK Inhibitor Therapy, Part 2: Patient Strategies for Self-Management	27 Jul 2021	00:17:50
In this podcast episode, Sandra E. Kurtin, PhD, ANP-C, AOCN, discusses nursing perspectives on avoiding adverse reactions to BTK inhibitor therapy. Topics in this second of 2 podcast episodes on avoiding AEs include: Patient adherence to oral medications Lifestyle changes Monitoring, recording, and reporting of AEs The role of the nurse The role of the patient AE management Presenter: Sandra E. Kurtin, PhD, ANP-C, AOCN Director, Advanced Practice and Clinical Integration The University of Arizona Cancer Center Assistant Professor, Clinical Medicine Adjunct Clinical Professor, Nursing The University of Arizona Tucson, Arizona CE/AAPA credit available by visiting the online program: https://bit.ly/3zMXFOp Link to full program, including downloadable slidesets: https://bit.ly/3iwN9Ub Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Strategies for Avoiding Adverse Reactions to BTK Inhibitor Therapy, Part 1: Drug–Drug and Drug–Food Interactions	27 Jul 2021	00:15:08
In this podcast episode,Sandra E. Kurtin, PhD, ANP-C, AOCN, discusses nursing perspectives on avoiding adverse reactions to BTK inhibitor therapy. Topics in this first of 2 podcasts on avoiding AEs include: Pharmacokinetics Drug metabolism Drug–drug interactions Drug–food interactions The role of CYP enzymes Foods to avoid Medication review Presenter: Sandra E. Kurtin, PhD, ANP-C, AOCN Director, Advanced Practice and Clinical Integration The University of Arizona Cancer Center Assistant Professor, Clinical Medicine Adjunct Clinical Professor, Nursing The University of Arizona Tucson, Arizona CE/AAPA credit available by visiting the online program: https://bit.ly/3zMXFOp Link to full program, including downloadable slidesets: https://bit.ly/3iwN9Ub Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	BTK Inhibitors in CLL and Lymphomas: Overview and Current Indications	23 Jul 2021	00:13:46
In this podcast episode, Beth Faiman, PhD, MSN, APRN-BC, AOCN, provides a nursing-focused overview on available BTK inhibitors in the treatment of CLL and lymphomas. Topics in this podcast include: Rationale for inhibiting BTK MOA of BTK inhibitors Approved BTK inhibitors Recent clinical trial findings Link to full program, including downloadable slidesets: https://bit.ly/3iwN9Ub Presenter: Beth Faiman, PhD, MSN, APRN-BC, AOCN Nurse Practitioner Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Adverse Events Associated with BTK Inhibitor Treatment	23 Jul 2021	00:12:30
In this podcast episode, Amy Goodrich, CRNP, discusses nursing perspectives on managing adverse events associated with BTK inhibitor therapy. Topics in this podcast include: BTK inhibitor selectivity BTK inhibitor adverse event profiles Ibrutinib intolerance Management of common adverse events Presenter: Amy Goodrich, RN, MSN, CRNP-AC Research Associate/Nurse Practitioner Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University Baltimore, Maryland CE/AAPA credit available by visiting the online program: https://bit.ly/3zMXFOp Link to full program, including downloadable slidesets: https://bit.ly/3iwN9Ub Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Radiopharmaceuticals in the Treatment of Metastatic Castration-Resistant Prostate Cancer	20 Jul 2021	00:21:17
In this episode, Chris Parker, MD, and Bertrand Tombal, MD, PhD, discuss the clinical implications of the latest data on radiopharmaceuticals in the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). Topics include: Data from the PEACE-3 trial on the effect of bone-protective agents on fracture risk with enzalutamide plus radium-223 Efficacy and toxicity of PSMA lutetium plus standard of care in the VISION trial Ongoing trials evaluating radionuclides in combination with other agents in metastatic CRPC Presenters: Chris Parker, MD Professor of Prostate Oncology Institute of Cancer Research Clinical Oncologist Department of Uro-oncology Royal Marsden Hospital Sutton, Surrey, United Kingdom Bertrand Tombal, MD, PhD Professor of Urology Institut de Recherche Clinique (IRC) Cliniques universitaires Saint-Luc Chairman Department of Surgery Cliniques universitaires Saint-Luc Brussels, Belgium Link to full program, including downloadable slides: https://bit.ly/36IEnNE Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	How to Integrate Novel Treatment Classes for R/R Myeloma Into Clinical Practice: Information on BCMA-Targeted Therapies	19 Jul 2021	00:15:44
In this podcast episode, Donna Catamero, ANP-BC, OCN, CCRC, highlights practical considerations for integrating anti-BCMA–targeted therapy into clinical practice for patients with multiple myeloma after multiple relapses. Don’t forget to listen to part 1 of this series with a discussion on other novel treatment options by Tiffany Richards, PhD, ANP-BC, AOCNP, Nurse Practitioner at the University of Texas MD Anderson Cancer Center. Presenter: Donna Catamero, ANP-BC, OCN, CCRC Associate Director, Myeloma Translational Research The Mount Sinai Health System New York, New York CE/AAPA credit available by visiting the online program: https://bit.ly/3zMXFOp Link to full program, including downloadable slidesets: https://bit.ly/3iwN9Ub Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Expert Answers to HCP Questions on CAR T-Cell Therapy	19 Jul 2021	00:18:02
In this episode, Caron A. Jacobson, MD; Jae H. Park, MD; and Noopur Raje, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in CAR T-cell therapy, with questions including: At what time in the treatment journey should CAR T-cell therapy be considered? How to select among 3 approved products for relapsed/refractory large B-cell lymphoma? How is CAR T-cell therapy best used for multiple myeloma? What qualities of bridging therapy are most preferred? When do patients receiving CAR T-cell therapy need COVID-19 or other vaccinations? How are steroids optimally used in managing CAR T-cell therapy–related toxicities? Presenters: Caron A. Jacobson, MD Assistant Professor Division of Medical Oncology Department of Medicine Harvard Medical School Dana-Farber Cancer Institute Boston, Massachusetts Jae H. Park, MD Associate Member Leukemia Service and Cellular Therapeutics Center Memorial Sloan Kettering Cancer Center New York, New York Noopur Raje, MD Director Center for Multiple Myeloma Massachusetts General Hospital Cancer Center Professor of Medicine Harvard Medical School Boston, Massachusetts Content based on an online CME program supported by an educational grant from Bristol-Myers Squibb. Link to full program: https://bit.ly/3BfbEOf Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	How to Integrate Novel Treatment Classes for R/R Myeloma Into Clinical Practice: Information on Selinexor, Venetoclax, and Melphalan Flufenamide	16 Jul 2021	00:12:53
In this podcast episode, Tiffany Richards, PhD, ANP-BC, AOCNP, highlights practical considerations for integrating novel treatments— selinexor, venetoclax, and melphalan flufenamide—into clinical practice for patients with multiple myeloma after multiple relapses. Check back to hear part 2 of this series with a discussion on BCMA-targeted therapy by Donna Catamero, ANP-BC, OCN, CCRC, Associate Director of Myeloma Translational Research at the Mount Sinai Health System. Presenter: Tiffany Richards, PhD, ANP-BC, AOCNP Nurse Practitioner Department of Lymphoma/Myeloma The University of Texas MD Anderson Cancer Center Houston, Texas CE/AAPA credit available by visiting the online program: https://bit.ly/3ee9Ivs Link to full program, including downloadable slidesets: https://bit.ly/3ee9Ivs Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Caring for Patients With Newly Diagnosed Multiple Myeloma	14 Jul 2021	00:12:22
In this podcast episode, Beth Faiman, PhD, MSN, APRN-BC, AOCN, discusses clinical considerations for diagnosis and optimal treatment selection for initial management of patients with multiple myeloma. Topics in this podcast include: IMWG criteria for diagnosing smoldering and active myeloma Risk stratification of smoldering myeloma with 2/20/20 criteria and active myeloma with R-ISS staging Individualizing initial treatment for ASCT-ineligible myeloma Selecting optimal initial treatment for ASCT-eligible myeloma Presenter: Beth Faiman, PhD, MSN, APRN-BC, AOCN Nurse Practitioner Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio CE/AAPA credit available by visiting the online program: https://bit.ly/3ee9Ivs Link to full program, including downloadable slidesets: https://bit.ly/3ee9Ivs Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Homologous Recombination Repair (HRR) Testing and Targeted Therapy in Prostate Cancer	28 Mar 2024	00:48:15
In this episode, Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, discuss optimal biomarker testing to guide treatment decisions in advanced prostate cancer, with topics including: Rationale for targeting PARP in prostate cancer with ARI combinations Study design nuances and findings from key randomized phase III clinical trials evaluating combination therapy with a PARP inhibitor and ARI, including PROpel, MAGNITUDE, and TALAPRO-2 FDA approvals of combination therapy with a PARP inhibitor and ARI, including a comparison of populations based on mutations Optimal biomarker testing for gene mutations in homologous recombination and mismatch repair pathways Tips for optimal coordination between pathology and medical oncology Presenters: Heather H. Cheng, MD, PhD Associate Professor Department of Medicine Division of Hematology and Oncology Attending Physician Department of Genitourinary Medical Oncology Fred Hutchinson Cancer Center Seattle, Washington Colin C. Pritchard, MD, PhD Co-Director Genetics and Solid Tumors Laboratory University of Washington Medical Center Professor Department of Laboratory Medicine and Pathology University of Washington Seattle, Washington Content based on an online CME program supported by an independent educational grant from Pfizer, Inc. Link to full program: https://bit.ly/3PFagxb Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Treatment Options for Patients With Multiple Myeloma After First Relapse	14 Jul 2021	00:13:34
In this podcast episode,Charise Gleason, MSN, NP-BC, AOCNP, discusses clinical considerations for patients with multiple myeloma after relapse on initial therapy. Topics in this podcast include: Strategies for monitoring for disease progression Disease, therapy, and patient considerations for treatment selection at first relapse Nursing implications and supportive care considerations for patients receiving therapy for relapsed disease Presenter: Charise Gleason, MSN, NP-BC, AOCNP Advanced Practice Provider Chief Winship Cancer Institute Adjunct Faculty Nell Hodgson Woodruff School of Nursing Emory University Atlanta, Georgia CE/AAPA credit available by visiting the online program: https://bit.ly/3ee9Ivs Link to full program, including downloadable slidesets: https://bit.ly/3ee9Ivs Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Precision Medicine in Gynecologic Cancers: Expert Answers to Your Questions	12 Jul 2021	00:07:35
In this episode, Linda R. Duska, MD, MPH; Robert L. Coleman, MD, FACOG, FACS; and Leslie Randall, MD, MAS, answer questions from an audience of healthcare professionals on topics related to the management of patients with endometrial and ovarian cancer including: Adding bevacizumab to chemotherapy in frontline endometrial cancer Lenvatinib and pembrolizumab in MSI-H/dMMR endometrial cancer PARP inhibitor maintenance in ovarian cancer Bevacizumab with or without PARP inhibitors in ovarian cancer Presenters: Linda R. Duska, MD, MPH Lawrence W. Penniston MD Family Professor in Women’s Oncology Research Division of Gynecologic Oncology Department of Obstetrics and Gynecology University of Virginia School of Medicine Charlottesville, Virginia Robert L. Coleman, MD, FACOG, FACS Gynecologic Oncologist and Chief Scientific Officer US Oncology, US Oncology Research The Woodlands, Texas Leslie Randall, MD, MAS Diane Harris Wright Professor and Director Division of Gynecologic Oncology Department of Obstetrics and Gynecology Massey Cancer Center Virginia Commonwealth University Richmond, Virginia Link to full program, including downloadable slidesets, expert commentaries, and on-demand webcast: https://bit.ly/3e6pZCM Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Expert Answers to Questions on Managing Neurofibromatosis Type 1 and MEK Inhibitors for NF1-Associated Plexiform Neurofibromas	12 Jul 2021	00:13:35
In this episode, Scott R. Plotkin, MD, PhD, and Brian D. Weiss, MD, answer questions from a healthcare professional audience on topics related to NF1 and plexiform neurofibromas including: Whole exome sequencing for diagnosis When to treat asymptomatic tumors Genetic testing of family members Choosing a MEK inhibitor Supportive care for acneiform rash Other RAS pathway inhibitors Presenters: Scott R. Plotkin, MD, PhD Executive Director Pappas Center for Neuro-Oncology Professor of Neurology Harvard Medical School Boston, Massachusetts Brian D. Weiss, MD Clinical Professor of Pediatrics Cancer and Blood Diseases Institute Division of Oncology Medical Director Solid Tumor Program Cincinnati Children’s Hospital Medical Center Cincinnati, Ohio Link to full program, including downloadable slidesets, expert commentaries, and on-demand webcast: https://bit.ly/3AXckHQ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Expert Answers to Questions on PARP Inhibitor Combinations in Prostate Cancer	30 Jun 2021	00:07:23
In this episode, Wassim Abida, MD, PhD; Joaquin Mateo, MD, PhD; and Charles J. Ryan, MD, answer questions from an audience of healthcare professionals on topics related to prostate cancer and PARP inhibition including: Germline and somatic mutation testing PARP inhibition in earlier stage disease PARP inhibitors plus AR-targeted therapy after progression on AR-targeted therapy PARP inhibition in taxane-sensitive patients Presenters: Wassim Abida, MD, PhD Assistant Member Assistant Attending Physician Genitourinary Oncology Service Department of Medicine Memorial Sloan Kettering Cancer Center New York, New York Joaquin Mateo, MD, PhD Group Leader Prostate Cancer Translational Research Vall d'Hebron Institute of Oncology Attending Physician Medical Oncology Vall d'Hebron University Hospital Barcelona, Spain Charles J. Ryan, MD Professor of Medicine B.J. Kennedy Chair in Clinical Medical Oncology Director, Division of Hematology, Oncology and Transplantation Department of Medicine University of Minnesota Oncologist Division of Hematology, Oncology and Transplantation University of Minnesota Health Clinics and Surgery Center Minneapolis, Minnesota Link to full program, including downloadable slidesets, expert commentaries, and on-demand webcast: https://bit.ly/3h1T5oR Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Immunotherapy for Advanced HCC: Current Options and Expert Answers to Clinician Questions	29 Jun 2021	00:11:37
In this episode, David Kaplan, MD, MSc, and Thomas Karasic, MD, review approved immunotherapy options for advanced HCC and answer key questions surrounding use of immune checkpoint inhibitors, with topics including: Current systemic therapy standards of care for patients with advanced HCC Use of single-agent immune checkpoint inhibitor therapy in the first-line setting Assessing bleeding risk Using immunotherapy in patients with active HBV or HCV infections Presenters: David Kaplan, MD, MSc Associate Professor Perelman School of Medicine University of Pennsylvania Director of Hepatology Corporal Michael J. Crescenz VA Medical Center Philadelphia, Pennsylvania Thomas Karasic, MD Assistant Professor of Medicine Department of Hematology-Oncology University of Pennsylvania Philadelphia, Pennsylvania Content based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group. Link to full program: https://bit.ly/39V6s72 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Expert Insight on Key Data From ASCO 2021 Informing Treatment for Endometrial, Ovarian, and Cervical Cancer	24 Jun 2021	00:38:12
In this episode, David Scott Miller, MD, FACOG, FACS, and Melissa M. Hardesty, MD, MPH, provide expert perspectives on new data from ASCO 2021 presented for endometrial, ovarian, and cervical cancers regarding: Results from a pilot study of pembrolizumab monotherapy in patients with Lynch-like vs sporadic MLH1-methylated endometrial cancer Updated analyses from the phase I GARNET trial, including data for patients with dMMR solid tumors (endometrial cancer and nonendometrial cancer cohorts) Final analyses from a study of mirvetuximab soravtansine plus bevacizumab in platinum-agnostic recurrent ovarian cancer Results from the randomized phase III BOOST trial evaluating optimal treatment duration of bevacizumab in combination with carboplatin and paclitaxel in ovarian cancer Highly anticipated results from the phase III OUTBACK trial of CRT ± adjuvant CT in women with locally advanced cervical cancer A post hoc, pooled analysis, from phase I and phase II data of bintrafusp alfa, a first-in-class bifunctional fusion protein comprising a TGF-βRII (TGF-β trap) fused to a human monoclonal antibody targeting PD-L1 Results from a prospective multicenter phase II trial evaluating anlotinib plus sutimlimab in recurrent/advanced cervical cancers Presenters: David Scott Miller, MD, FACOG, FACS Amy and Vernon E. Faulconer Distinguished Chair in Medical Science Director and Dallas Foundation Chair in Gynecologic Oncology Professor of Obstetrics & Gynecology University of Texas Southwestern Medical Center Medical Director of Gynecologic Oncology Chair, Cancer Committee Parkland Health & Hospital System Dallas, Texas Melissa M. Hardesty, MD, MPH Affiliate Associate Professor OB/GYN/GYN Oncology University of Alaska Anchorage Gynecologic Oncologist and Managing Partner Alaska Women’s Cancer Care Anchorage, Alaska Content supported by an educational grant from GlaxoSmithKline. Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries: https://bit.ly/3dAttwi Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Optimizing Therapy for Relapsed/Refractory Multiple Myeloma: Expert Answers to Your Questions	17 Jun 2021	00:21:31
In this podcast episode, Suzanne Lentzsch, MD, PhD, and Saad Z. Usmani, MD, MBA, FACP, discuss how they select optimal treatment for relapsed/refractory (R/R) multiple myeloma (MM) and answer audience questions from a live webinar. Topics include: Selecting optimal triplet regimen after first relapse Sequencing treatment options after multiple relapses Managing patient expectations when selecting treatments Emerging treatment options for R/R MM Presenters: Suzanne Lentzsch, MD, PhD Director, Multiple Myeloma and Amyloidosis Program Professor of Medicine Division of Hematology/Oncology Columbia University Medical Center New York, New York Saad Z. Usmani, MD, MBA, FACP Clinical Professor of Medicine Department of Hematologic Oncology & Blood Disorders Division Chief Plasma Cell Disorders Division Levine Cancer Institute/Atrium Health Charlotte, North Carolina Supported by educational grants from Amgen; Bristol-Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Oncopeptides. Link to full program, including an downloadable slidesets and an on-demand webcast: https://bit.ly/3gjr62p Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Experts Answer FAQs on Biomarker-Driven Therapy for Non-Small-Cell Lung Cancer	19 May 2021	00:27:05
In this episode, Nathan Pennell, MD, PhD; Jamie E. Chaft, MD; and Stephen V. Liu, MD, answer questions asked by an audience of healthcare professionals during a live CCO webinar on biomarker-driven therapies for NSCLC. Topics include: Choosing between immune checkpoint inhibitor monotherapy and combination therapy with an immune checkpoint inhibitor plus chemotherapy for newly diagnosed NSCLC Incorporating newly approved immunotherapies into practice Evolving guidelines and recommendations for biomarker testing RNA- vs DNA-based next-generation sequencing Interpretation of NGS results Use of frontline TKI therapy for patients with CNS metastases Future role of KRAS inhibitors in the treatment of advanced NSCLC Improving rates of biomarker testing in lung cancer Presenters: Nathan Pennell, MD, PhD Professor Director, Cleveland Clinic Lung Cancer Medical Oncology Program Department of Hematology and Medical Oncology Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio Jamie E. Chaft, MD Associate Attending Physician Thoracic Oncology Service Memorial Sloan Kettering Cancer Center New York, New York Stephen V. Liu, MD Associate Professor of Medicine Department of Medical Oncology Lombardi Comprehensive Cancer Center Georgetown University Washington, DC Supported by educational grants from Amgen; Lilly; Regeneron Pharmaceuticals, Inc.; and Sanofi Genzyme. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com. Link to full program, including an downloadable slidesets and an on-demand webcast: https://bit.ly/3npjyyb Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC	18 May 2021	00:24:34
In this episode,Egbert F. Smit, MD, PhD; David Planchard, MD, PhD; and Helena A. Yu, MD, answer audience questions from a live webinar regarding clinical data on antibody–drug conjugates in NSCLC including: Biopsies and biomarker testing considerations Tumor heterogeneity and targeting of brain metastases Liquid biopsies Sequencing of ADCs following previous therapy Toxicity management Presenters: Egbert F. Smit, MD, PhD Professor Department of Pulmonary Diseases Leiden University Medical Center Leiden, Netherlands Department of Thoracic Oncology Netherlands Cancer Institute Amsterdam, Netherlands David Planchard, MD, PhD Head of Thoracic Group Department of Medical Oncology Institute Gustave Roussy Villejuif, France Helena A. Yu, MD Assistant Attending Department of Medicine Memorial Sloan Kettering Cancer Center New York, New York Content based on an online CME program supported by an educational grant from Daiichi Sankyo, Inc. Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC - Oncology - Clinical Care Options (clinicaloptions.com) Link to full program: https://bit.ly/3fr2G6G Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Immunotherapy for Advanced HCC: Case Series	17 May 2021	00:25:37
In this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, discuss key considerations key considerations for hepatologists, oncologists, and other healthcare professionals in the contemporary use of immune checkpoint inhibitors for treating specific case patients with advanced hepatocellular carcinoma, including: First-line systemic treatment for a patient with Child-Pugh A liver function and no elevated bleeding risk First-line systemic treatment for a patient with Child-Pugh A liver function and elevated bleeding risk First-line systemic treatment for a patient with Child-Pugh B liver function Second-line systemic treatment for a patient previously receiving atezolizumab plus bevacizumab Management of immune-mediated hepatitis in a patient with HBV receiving an immune checkpoint inhibitor Presenters: Amit G. Singal, MD, MS Chief of Hepatology Medical Director, Liver Tumor Program Professor, Department of Internal Medicine UT Southwestern Medical Center Dallas, Texas Lipika Goyal, MD Lead of the Liver Cancer Research Program Assistant Professor of Medicine Harvard Medical School Massachusetts General Hospital Cancer Center Boston, Massachusetts Content based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group. Link to full program: https://bit.ly/39V6s72 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Real-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast Cancer	18 Mar 2024	00:36:29
In this podcast episode, Sara M. Tolaney, MD, MPH, and Melinda Telli, MD, delve into the critical aspects of the current therapeutic landscape for patients with unresectable or metastatic HER2-low, hormone receptor–positive, and triple-negative breast cancer, including: Challenges with the pathologic testing for HER2-low expression Optimal treatment of patients with HER2-low advanced breast cancer Role of TROP-2–targeted therapies Management of ADC-associated adverse events to optimize treatment outcomes ADCs on the horizon for patients with advanced breast cancer Presenters: Sara M. Tolaney, MD, MPH Chief, Division of Breast Oncology Dana-Farber Cancer Institute Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Melinda Telli, MD Professor of Medicine Stanford University School of Medicine Director, Breast Cancer Program Stanford Cancer Institute Palo Alto, California Content based on an online CME program supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc. Link to full program: https://bit.ly/49WxRBM Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From Germany	13 May 2021	00:25:45
In this episode, Georgios Gakis, MD, and Mario Wolfgang Kramer, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in Germany. Topics include: Guideline changes for first-line UC based on data from JAVELIN Bladder 100 trial on avelumab maintenance after chemotherapy Results from IMvigor130 and KEYNOTE-361 trials on concurrent immune checkpoint inhibition plus chemotherapy When to consider first-line treatment with immune checkpoint inhibitor monotherapy Utility of PD-L1 as biomarker for immune checkpoint inhibitor–based therapy Presenters: Georgios Gakis, MD Professor of Urology, Staff Urologist University Hospital of Würzburg Würzburg, Germany Mario Wolfgang Kramer, MD, PhD Consultant Urologist Vice Director, Urology University Hospital Schlewig-Holstein Campus Lübeck Lübeck, Germany Content based on an online IME program supported by an educational grant from Pfizer and EMD Serono, Inc. Link to full program, including associated downloadable slidesets and on-demand webcast: https://bit.ly/3kJC5SL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Managing Toxicities Associated With FGFR Inhibitors in Urothelial Cancer and Beyond	04 May 2021	00:20:58
In this episode, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss toxicities associated with FGFR inhibitors used in the treatment of urothelial cancer and other malignancies Presenters: Ignacio Durán, MD, PhD Associate Professor GU Oncology Program Leader Department of Medical Oncology Hospital Universitario Marques de Valdecilla-Idival Santander, Spain Alison Birtle, MD, FRCP, FRCR Honorary Senior Lecturer Faculty of Health and Medicine University of Manchester Manchester, United Kingdom Consultant Oncologist Rosemere Cancer Centre Lancashire Teaching Hospitals Preston, Lancashire, United Kingdom Content based on an online IME program supported by educational grants from Janssen Pharmaceutica NV. Link to full program: http://bit.ly/3cf28jH Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Optimizing the Timing and Sequencing of Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer	28 Apr 2021	00:15:38
In this episode, Joleen Hubbard, MD, and John L. Marshall, MD, discuss use of the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including: Key data supporting the clinical use of these agents Optimal sequencing and timing of use Dosing considerations Key adverse events Presenters: Joleen Hubbard, MD Associate Professor Gastrointestinal Oncologist Medical Oncology Mayo Clinic Rochester, Minnesota John L. Marshall, MD Chief, Division of Hematology/Oncology Department of Medicine Georgetown University Hospital Washington, DC Content based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc. Link to full program: BITLY NEEDED Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Expert Answers to Questions on Contemporary Management of Multiple Myeloma	22 Apr 2021	00:31:59
In this episode, Shaji K. Kumar, MD; Thomas G. Martin, MD; Philippe Moreau, MD; S. Vincent Rajkumar, MD, and Jesús F. San-Miguel, MD, PhD, answer audience questions from a recent Clinical Care Options live webinar on managing multiple myeloma. Topics include: Approaches for managing smoldering multiple myeloma Insights on new strategies for managing newly diagnosed multiple myeloma Incorporating newly approved agents in the frontline and early relapse setting Choosing and sequencing BCMA-targeted therapies Managing patients with refractory multiple myeloma Presenters: Shaji K. Kumar, MD Mark and Judy Mullins Professor of Hematological Malignancies Chair, Myeloma Amyloidosis Dysproteinemia Group Consultant, Division of Hematology Mayo Clinic Rochester, Minnesota Thomas G. Martin, MD Clinical Professor of Medicine Associate Director, Myeloma Program University of California, San Francisco Medical Center San Francisco, California Philippe Moreau, MD Professor of Clinical Hematology Head, Hematology Department University Hospital Hôtel-Dieu Nantes, France S. Vincent Rajkumar, MD Edward W. and Betty Knight Scripps Professor of Medicine Mayo Clinic Rochester, Minnesota Jesús F. San-Miguel, MD, PhD Director of Clinical and Translational Medicine Universidad de Navarra Pamplona, Spain Supported by educational grants from Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Karyopharm and Oncopeptides. Link to full program, including downloadable slidesets and expert commentaries: https://bit.ly/39MWNid Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Combining PARP inhibitors With Other Treatments for Men With Prostate Cancer: Clinical Trial Updates	19 Apr 2021	00:22:40
In this episode, Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, consider the potential implications of ongoing and planned clinical trials using PARP inhibitors in combination with other therapies to treat men with prostate cancer including: PARP inhibitors combined with androgen receptors Phase III trials of PARP inhibitors with androgen receptor–directed therapy PARP inhibitors combined with immunotherapy PARP inhibitors and DNA damaging agents Presenters: Karim Fizazi, MD, PhD Full Professor Cancer Medicine Institut Gustave Roussey Villejuif, France Joaquin Mateo, MD, PhD Attending Physician Medical Oncology Vall d’Hebron University Hospital, Barcelona, Spain Content is part of an online program supported by an educational grant from Pfizer Inc. Link to full program, including associated downloadable Podcast Pearls slidesets, expert analysis, and expert commentary: https://bit.ly/3spLzqa Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Rationale for Combining PARP Inhibitors With Other Therapies in Prostate Cancer	15 Apr 2021	00:13:42
In this episode, Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, discuss the underlying rationale for using PARP inhibitors in combination with other therapies to treat men with prostate cancer including: Possible synergy between PARP inhibitors and androgen receptor–directed therapy Rationale for PARP inhibitors and immunotherapy combinations Benefits and challenges of combining DNA damaging agents and PARP inhibitor Presenters: Karim Fizazi, MD, PhD Full Professor Cancer Medicine Institut Gustave Roussey Villejuif, France Joaquin Mateo, MD, PhD Attending Physician Medical Oncology Vall d’Hebron University Hospital, Barcelona, Spain Content is part of an online program supported by an educational grant from Pfizer Inc. Link to full program, including associated downloadable Podcast Pearls slidesets, expert analysis, and expert commentary: https://bit.ly/3spLzqa Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Expert Insight on Key Data From SGO 2021 Informing Treatment for Endometrial and Ovarian Cancer	06 Apr 2021	00:33:58
In this episode, Jubilee Brown, MD, and Ursula Matulonis, MD, provide expert perspectives on new data from SGO 2021 presented for endometrial and ovarian cancer including: Results from KEYNOTE-775, a phase III trial of lenvatinib plus pembrolizumab in advanced endometrial cancer Results from the confirmatory phase III ARIEL4 evaluating rucaparib vs chemotherapy in BRCA-mutated relapsed ovarian cancer 5-year follow-up from SOLO-1 trial of olaparib vs placebo in BRCA-mutated, newly diagnosed ovarian cancer Long-term follow-up results from the phase III ENGOT-OV16/NOVA trial of niraparib in patients with recurrent ovarian cancer OPAL: a phase II study evaluating dostarlimab, bevacizumab, and niraparib in platinum-resistant ovarian cancer Presenters: Jubilee Brown, MD Professor and Director of Gynecologic Oncology Levine Cancer Institute Atrium Health Charlotte, North Carolina Ursula Matulonis, MD Chief, Division of Gynecologic Oncology Brock Wilson Family Chair Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School Boston, Massachusetts Content supported by an educational grant from GlaxoSmithKline. Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries: https://bit.ly/3dAttwi Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Expert Answers to Questions on PARP Inhibition for Prostate Cancer	06 Apr 2021	00:10:51
In this episode, Charles J. Ryan, MD, and Neal D. Shore, MD, FACS, answer questions from a healthcare professional audience on topics related to prostate cancer and PARP inhibition including: Germline and somatic mutation testing Managing adverse events with PARP inhibitors Resistance to PARP inhibitors Implications of monoallelic vs biallelic BRCA mutations ATM mutations and PARP inhibitor sensitivity Presenters: Charles J. Ryan, MD Professor of Medicine B.J. Kennedy Chair in Clinical Medical Oncology Director, Division of Hematology, Oncology and Transplantation Department of Medicine University of Minnesota Oncologist Division of Hematology, Oncology and Transplantation University of Minnesota Health Clinics and Surgery Center Minneapolis, Minnesota Neal D. Shore, MD, FACS Director Carolina Urologic Research Center Atlantic Urology Clinics Myrtle Beach, South Carolina Link to full program, including downloadable slidesets, expert commentaries, and on-demand webcast: https://bit.ly/2P31ZqF Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Expert Insights on Highlights From ASH 2020 on Lymphomas/CLL	26 Mar 2021	00:17:06
In this episode, Jeremy S. Abramson, MD, MMSc, discusses highlights of the key data from ASH 2020 on the treatment of patients with lymphomas/CLL, with topics including: Approved and Investigational Targeted Therapeutics for CLL Investigational CAR T-Cell Therapy for Indolent Lymphomas, CLL, and Mantle Cell Lymphoma Bispecific Antibodies and Other Investigational Targeted Agents for Lymphomas Treatment for Older Patients With Hodgkin Lymphoma Presenters: Jeremy S. Abramson, MD, MMSc Associate Professor Department of Medicine Harvard Medical School Director, Center for Lymphoma Massachusetts General Hospital Boston, Massachusetts Content based on an online CME program supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc.; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc.; Novartis; PharmaEssentia Corp.; Seattle Genetics; and Takeda Oncology. Link to full program: https://bit.ly/3tyQ9nG Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Improving Outcomes in EGFR-Mutated Non-Small-Cell Lung Cancer: Global Insights on Evolving Practice Standards	25 Mar 2021	00:32:37
In this episode, Enriqueta Felip, MD, PhD, and Matthew Gubens, MD, MS, discuss evolving practice standards for EGFR-mutated non-small-cell lung cancer with topics including: Biomarker testing and strategies Optimal first-line therapy in patients with NSCLC Management of patients with CNS disease Selecting therapy for patients with noncanonical mutations Management strategies after progression on first-line EGFR TKI therapy Selecting therapy for patients with early stage disease Presenters: Enriqueta Felip, MD, PhD Head, Thoracic Oncology Unit Oncology Service Vall d'Hebron University Hospital Barcelona, Spain Matthew Gubens, MD, MS Associate Professor Thoracic Oncology University of California, San Francisco San Francisco, California Content based on an online CME program supported by an educational grant from AstraZeneca. Link to full program, including associated downloadable slidesets: https://bit.ly/2PpFFHM Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Current Considerations for Adverse Event Management With HER3-Directed Agents	26 Dec 2023	00:12:33
The third and final episode in a 3-part series covers the safety profile of and considerations for managing adverse events associated with HER3-targeted antibody–drug conjugates, including patritumab deruxtecan (HER3-DXd) and others, in the setting of lung cancer. Presenters in this series include: Rebecca S. Heist, MD, MPH Associate Professor of Medicine Harvard Medical School Medical Oncology Massachusetts General Hospital Boston, Massachusetts Helena Yu, MD Associate Attending Department of Medicine Memorial Sloan Kettering Cancer Center New York, New York Supported by an educational grant from Daiichi Sankyo, Inc. Link to full program, including a downloadable highlights slideset: https://bit.ly/48ecElW Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Targeting FGFR in Urothelial Cancer and Beyond	23 Mar 2021	00:20:18
In this episode, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, interpret the latest clinical data on targeting FGFR in urothelial cancer Presenters: Ignacio Durán, MD, PhD Associate Professor GU Oncology Program Leader Department of Medical Oncology Hospital Universitario Marques de Valdecilla-Idival Santander, Spain Alison Birtle, MD, FRCP, FRCR Honorary Senior Lecturer Faculty of Health and Medicine University of Manchester Manchester, United Kingdom Consultant Oncologist Rosemere Cancer Centre Lancashire Teaching Hospitals Preston, Lancashire, United Kingdom Content based on an online IME program supported by educational grants from Janssen Pharmaceutica NV. Link to full program: http://bit.ly/3cf28jH Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Expert Answers to HCP Questions on Pancreatic Cancer Treatment	22 Mar 2021	00:13:12
In this episode, Michael J. Pishvaian, MD, PhD, and Rachna Shroff, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in pancreatic cancer treatment, with questions including: What is your preferred regimen for neoadjuvant therapy in patients with resectable disease? How do you sequence therapy for patients with metastatic pancreatic cancer? How can you manage a patient who develops significant diarrhea with FOLFIRINOX? Are cisplatin and oxaliplatin equally efficacious for patients with BRCA-mutant disease? How should maintenance olaparib be used? Presenters: Michael J. Pishvaian, MD, PhD Associate Professor of Oncology Director, Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs NCR Kimmel Cancer Center at Sibley Memorial Hospital John Hopkins University School of Medicine Washington, DC Rachna Shroff, MD Associate Professor of Medicine Chief, Section of GI Medical Oncology Director, UACC Clinical Trials Office The University of Arizona Cancer Center Tucson, Arizona Content based on an online CME program supported by educational grants from Bristol-Myers Squibb and Ipsen Group. Link to full program: http://bit.ly/314BALT Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Expert Answers to HCP Questions on CAR T-Cell Therapies in Lymphoma	18 Mar 2021	00:11:09
In this episode, Frederick L. Locke, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with lymphomas, with questions including: How does the recent approval of lisocabtagene maraleucel and the expanded indication for axicabtagene ciloleucel add to the treatment landscape for DLBCL? Do you see CAR T-cell therapy ever being used in the first-line setting for DLBCL? How should physicians select patients for CAR T-cell therapy vs ASCT in DLBCL? How should physicians sequence CAR T-cell therapy vs BTK inhibitors in MCL? Presenter: Frederick L. Locke, MD Co-Leader Moffitt Immuno-Oncology Program Vice Chair and Associate Member Department of Blood and Marrow Transplant and Cellular Immunotherapy Research Director and Medical Director Immune Cell Therapy Program Moffitt Cancer Center Tampa, Florida Content based on an online CME program supported by educational grants from Bristol-Myers Squibb and Kite Pharma. Link to full program: https://bit.ly/3rDeFCV Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Frequently Asked Questions on Emerging Antibody–Drug Conjugates in the Treatment of Advanced Non-Small-Cell Lung Cancer	17 Mar 2021	00:07:40
In this episode, D. Ross Camidge, MD, PhD, and Joel W. Neal, MD, PhD, answer questions on investigational antibody-drug conjugates for advanced NSCLC Presenters: Ross Camidge, MD, PhD Professor of Medicine/Oncology University of Colorado Cancer Center Aurora, Colorado Joel W. Neal, MD, PhD Associate Professor of Medicine Division of Oncology Department of Medicine Stanford University Attending Physician Stanford Cancer Institute Palo Alto, California Content based on an online IME program supported by educational grants from Daiichi Sankyo, Inc . Link to full program: http://bit.ly/3twpIyl Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Expert Answers to HCP Questions on CAR T-Cell Therapies in Myeloma and Management of Key Toxicities	12 Mar 2021	00:11:43
In this episode, Noopur Raje, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with multiple myeloma and key toxicities associated with CAR T-cell therapy, with questions including: Now that belantamab mafodotin is approved for relapsed/refractory multiple myeloma, what are your thoughts on how BCMA-directed CAR T-cell therapy might be sequenced? Is there reason to think CAR T-cell therapy would still be efficacious following belantamab mafodotin? Could BCMA-directed CAR T-cell therapy replace transplant in the first-line setting for multiple myeloma? What are key considerations surrounding the use of tocilizumab for managing cytokine-release syndrome? What are some of the longer-term toxicities associated with CAR T-cell therapy? When do they emerge and how long do they typically last? Presenter: Noopur Raje, MD Professor of Medicine Harvard Medical School Director Center for Multiple Myeloma Massachusetts General Hospital Cancer Center Boston, Massachusetts Content based on an online CME program supported by educational grants from Bristol-Myers Squibb and Kite Pharma. Link to full program: http://bit.ly/3rDeFCV Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Expert Insights on Highlights From ASH 2020 on Multiple Myeloma	12 Mar 2021	00:38:31
In this episode, Dr. Shaji Kumar from the Mayo Clinic and Dr. Sagar Lonial from Emory University discuss highlights of the key data from ASH 2020 on the treatment of patients with multiple myeloma. Topics include: Newly diagnosed multiple myeloma Relapsed/refractory multiple myeloma Anti-BCMA therapy: CAR T-cells Anti-BCMA therapy: bispecific antibodies Anti-BCMA therapy: antibody–drug conjugates Novel targeted agents for relapsed/refractory multiple myeloma Presenters: Shaji K. Kumar, MD Mark and Judy Mullins Professor of Hematological Malignancies Chair, Myeloma Amyloidosis Dysproteinemia Group Consultant, Division of Hematology Mayo Clinic Rochester, Minnesota Sagar Lonial, MD Professor and Chair Department of Hematology and Medical Oncology Chief Medical Officer Winship Cancer Institute of Emory University Atlanta, Georgia Link to the CCO website: http://bit.ly/30EqUn0 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Expert Insights on Key Data From ASH 2020 on Acute and Chronic Leukemias	26 Feb 2021	00:26:19
In this episode, Jorge Cortes, MD, and Eunice S. Wang, MD, discuss the clinical implications of 3 key studies in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) presented at the virtual ASH 2020 annual conference. Topics include: The macrophage immune checkpoint inhibitor magrolimab in AML The STAMP inhibitor asciminib in CML (the ASCEMBL trial) Optimal dosing for the TKI ponatinib in CML Presenters: Jorge Cortes, MD Director, Georgia Cancer Center Eminent Scholar, Georgia Research Academy Augusta, Georgia Eunice S. Wang, MD Professor, Oncology Chief, Leukemia Service Department of Medicine Roswell Park Comprehensive Cancer Center Buffalo, New York Content supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc; Novartis; PharmaEssentia Corp; Seattle Genetics; and Takeda Oncology. Link to full program and Capsule Summary downloadable slidesets: https://bit.ly/3tyQ9nG Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Expert Insight on Key Data From WCLC 2020 in Early-Stage Lung Cancer	24 Feb 2021	00:15:12
In this episode, Jamie E. Chaft, MD, provides her expert perspective on new data from WCLC 2020 in early-stage NSCLC, with topics including: Updated results from ADAURA on HRQoL and DFS outcomes with or without postoperative chemotherapy after adjuvant osimertinib An analysis of the ongoing ITACA study of personalizing chemotherapy based on biomarkers of drug resistance FDG PET/CT adaptive radiotherapy in RTOG 1106 The TALENT study in Taiwan screening nonsmokers for lung cancer Presenter: Jamie E. Chaft, MD Associate Attending Physician Thoracic Oncology Service Memorial Sloan Kettering Cancer Center New York, New York Content supported by educational grants from Amgen; Bristol-Myers Squibb; Ipsen Biopharmaceuticals; Janssen Pharmaceutica NV; Jazz Pharmaceuticals; Regeneron Pharmaceuticals, Inc. & Sanofi Genzyme; and Takeda Oncology. Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries: http://bit.ly/2NzE6X6 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From Argentina	22 Feb 2021	00:21:16
In this episode, José Ignacio Nolazco, MD, and Alejandro Nolazco, MD, discuss in Spanish the latest immuno-oncology developments in the treatment of urothelial cancer from an Argentinian perspective. Presenters: José Ignacio Nolazco, MD Urology Fellow Hospital Universitario Austral Buenos Aires, Argentina Alejandro Nolazco, MD Associate Professor Department of Urology Universidad Austral and Universidad Católica Argentina Buenos Aires, Argentina Content based on an online IME program supported by educational grants from EMD Serono, Inc and Pfizer. Link to full program, including associated downloadable slidesets and on-demand Webcast: https://bit.ly/3kJC5SL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Expert Insights on Key Data From ASH 2020 on Nonmalignant Hematologic Disorders	10 Feb 2021	00:40:17
In this episode, Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD, provide their clinical perspectives on new data from ASH 2020 on nonmalignant hematologic disorders, with topics including: Use of mycophenolate mofetil plus corticosteroids vs standard corticosteroid treatment in patients with ITP from the phase III FLIGHT study Analysis of an ongoing phase I/II trial of rilzabrutinib reporting safety and efficacy in the long-term extension for adult patients with relapsed/refractory ITP New data from the phase III HOPE-B study of etranacogene dezaparvovec gene therapy, using an AAV5-vector to deliver the Padua variant of the factor IX gene in patients with hemophilia B An update from the phase I/II CLIMB THAL-111/SCD-121 studies reporting safety and efficacy on the first 10 patients receiving CTX001 with at least 3 months of follow-up Primary analysis from the phase III REACH3 trial evaluating ruxolitinib, an oral JAK1/2 inhibitor, in combination with steroids and calcineurin inhibitors, as a treatment for steroid-refractory or steroid-dependent chronic GVHD Top-line results from the phase II ROCKstar study of belumosudil, a ROCK2 kinase inhibitor, in patients with heavily pretreated chronic GVHD Phase I data from the GRAVITAS-119 study of JAK1 inhibitor itacitinib plus calcineurin inhibitors as prophylaxis treatment for acute GVHD Presenters: Hanny Al-Samkari, MD Instructor Department of Medicine Harvard Medical School Attending Hematologist and Clinical Investigator Division of Hematology Oncology Massachusetts General Hospital Boston, Massachusetts Sujit Sheth, MD Professor Department of Pediatrics Weill Cornell Medicine New York, New York Mark A. Schroeder, MD Associate Professor of Medicine Division of Oncology Department of Medicine Washington University School of Medicine in St Louis St Louis, Missouri Content supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc.; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc.; Novartis; PharmaEssentia Corp.; Seattle Genetics; and Takeda Oncology. Link to full program, including downloadable slidesets, and on-demand Webcasts: http://bit.ly/3tyQ9nG Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Unpacking the Potential of HER3-Targeted Therapy in NSCLC	26 Dec 2023	00:15:24
This second episode in a 3-part series on HER3-targeted agents in NSCLC covers current clinical trials with HER3-targeted therapy, including: Recent data on patritumab deruxtecan (HER3-DXd) in the HERTHENA-Lung01 trial The EGFRxHER3 bispecific antibodies BL-B01D1 and izalontamab The HER2xHER3 bispecific antibody zenocutuzumab The HER3-targeted antibody–drug conjugate SHR-A2009 Presenters in this series include: Rebecca S. Heist, MD, MPH Associate Professor of Medicine Harvard Medical School Medical Oncology Massachusetts General Hospital Boston, Massachusetts Helena Yu, MD Associate Attending Department of Medicine Memorial Sloan Kettering Cancer Center New York, New York Supported by an educational grant from Daiichi Sankyo, Inc. Link to full program, including a downloadable highlights slideset: https://bit.ly/48ecElW Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Expert Insights on Key Data From ASH 2020 on Myelodysplastic Syndromes and Myeloproliferative Neoplasms	05 Feb 2021	00:23:43
In this episode, Amy E. DeZern, MD, MHS, and Srdan Verstovsek, MD, provide medical oncology and hematology perspectives on new data from ASH 2020 in MDS and MPNs, with topics including: 3-year OS results with RIC allogeneic transplantation in patients with higher-risk MDS in the BMT CTN 1102 study A post hoc analysis of phase II data on the addition of pevonedistat to azacitidine in higher-risk MDS patients 5-year results of ropeginterferon α-2b in polycythemia vera from the CONTINUATION-PV study Phase II results of luspatercept for anemia in patients with myelofibrosis who are transfusion dependent Analysis of clinical benefit in patients with myelofibrosis and OS benefit from imetelstat. Presenters: Amy E. DeZern, MD, MHS Associate Professor Oncology and Medicine The Johns Hopkins University School of Medicine Baltimore, Maryland Srdan Verstovsek, MD, PhD Professor Division of Cancer Medicine Department of Leukemia The University of Texas MD Anderson Cancer Center Houston, Texas Content supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc; Novartis; PharmaEssentia Corp; Seattle Genetics; and Takeda Oncology. Link to full program and Capsule Summary downloadable slidesets: http://bit.ly/3tyQ9nG Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Expert Answers to Questions on Contemporary Management of Hemophilia A	04 Feb 2021	00:28:07
In this episode, Michael Callaghan, MD; Miguel A. Escobar, MD; and Rebecca Kruse-Jarres, MD, MPH, answer questions from a clinician audience on topics related to hemophilia management including: Maintaining long-term musculoskeletal health Identifying patients most likely to benefit from pharmacokinetics-guided prophylaxis Managing combination therapies in older patients with comorbidities Youngest age at which patients can be considered for emicizumab Development of resistance to emicizumab Switching recombinant factor therapies Using bypassing agents with emicizumab for breakthrough bleeds in patients with inhibitors Potential clinical role of extending FVIII half-life with BIVV001 Considerations when dosing emicizumab monthly Presenters: Michael Callaghan, MD Associate Professor Department of Hematology Wayne State University Hematologist Division of Hematology/Oncology Children’s Hospital of Michigan Detroit, Michigan Miguel A. Escobar, MD Professor of Medicine and Pediatrics Department of Hematology University of Texas Health Science Center McGovern Medical School Director Gulf States Hemophilia and Thrombophilia Center Houston, Texas Rebecca Kruse-Jarres, MD, MPH Professor Department of Medicine University of Washington Executive/Medical Director Washington Institute for Coagulation Seattle, Washington Content supported by educational grants from Genentech, a member of the Roche Group; Sanofi Genzyme Corporation; and Takeda Pharmaceutical Company Ltd. Link to full program, including downloadable slidesets, expert commentaries, and on-demand Webcast: http://bit.ly/2MW5uhi Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
	Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From Italy	04 Feb 2021	00:25:33
In this episode, Guiseppe Procopio, MD, and Cora N. Sternberg, MD, FACP, discuss in Italian the latest immuno-oncology developments in the treatment of urothelial cancer. Presenters: Guiseppe Procopio, MD Head of the Medical Oncology Genitourinary, Istituto Nazionale Tumori Medical Oncology Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy Cora N. Sternberg, MD, FACP Professor of Medicine Department of Hematology/Oncology Weill Cornell Medicine New York, New York, USA Content based on an online IME program supported by educational grants from EMD Serono, Inc and Pfizer. Link to full program, including associated downloadable slidesets and on-demand Webcast: http://bit.ly/3kJC5SL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

À propos Méthodologie Contact Me soutenir Politique de confidentialité